Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis and Its Clinical Application in Evidencio.
Gosselt HR, Verhoeven MMA, de Rotte MCFJ, Pluijm SMF, Muller IB, Jansen G, Tekstra J, Bulatović-Ćalasan M, Heil SG, Lafeber FPJG, Hazes JMW, de Jonge R. Gosselt HR, et al. Rheumatol Ther. 2020 Dec;7(4):837-850. doi: 10.1007/s40744-020-00230-7. Epub 2020 Sep 14. Rheumatol Ther. 2020. PMID: 32926395 Free PMC article.
Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study.
Roest LH, Kosse LJ, van Lint JA, Gosselt HR, Scholl JHG, van Puijenbroek E, Vonkeman HE, Tas SW, Nurmohamed MT, van den Bemt BJF, Jessurun NT. Roest LH, et al. Among authors: gosselt hr. Expert Opin Drug Saf. 2023 Mar;22(3):203-211. doi: 10.1080/14740338.2022.2115479. Epub 2022 Aug 28. Expert Opin Drug Saf. 2023. PMID: 36036179
Analysis and visualization of the course and burden over time of adverse drug reactions (ADRs) attributed to TNFα-inhibitors in patients with inflammatory rheumatic diseases (IRDs).
de Boer M, Gosselt HR, Jansen J, van Doorn MBA, Hoentjen F, Nurmohamed MT, Spuls PI, Tas SW, Vonkeman HE, Jessurun NT. de Boer M, et al. Among authors: gosselt hr. Expert Opin Drug Saf. 2023 Mar;22(3):195-202. doi: 10.1080/14740338.2022.2110237. Epub 2022 Aug 10. Expert Opin Drug Saf. 2023. PMID: 35946722
14 results